Stephen J. Pettitt
0000-0003-3313-3857
Publication & Citation Trends
Publications
0 total
Correction to: Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells.
Cited by 0
Semantic Scholar
Tumour specific HORMAD1 expression perturbs mitotic arrest and drives sensitivity to mitotic kinase inhibitors
Cited by 0
Semantic Scholar
The PARP inhibitor talazoparib synergizes with reovirus to induce cancer killing and tumour control in vivo in mouse models
Cited by 5
Semantic Scholar
The transcriptomic architecture of common cancers reflects synthetic lethal interactions OA
Cited by 6
Semantic Scholar
Autocrine interferon poisoning mediates ADAR1-dependent synthetic lethality in BRCA1/2-mutant cancers
Cited by 2
Semantic Scholar
PPP2R1A mutations cause ATR inhibitor sensitivity in ovarian clear cell carcinoma OA
Cited by 9
Semantic Scholar
CDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic Lethality OA
Cited by 2
Semantic Scholar
Research Topics
PARP inhibition in cancer therapy
(65)
DNA Repair Mechanisms
(60)
CRISPR and Genetic Engineering
(51)
BRCA gene mutations in cancer
(36)
Sarcoma Diagnosis and Treatment
(15)
Affiliations
Academy of Medical Sciences
Target (United States)
Institute of Cancer Research
Chinese Academy of Medical Sciences & Peking Union Medical College
Breast Cancer Now